SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Rosencher Nadia)
 

Sökning: WFRF:(Rosencher Nadia) > Rivaroxaban versus ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004575naa a2200649 4500
001oai:lup.lub.lu.se:d8184a98-8c7f-41d6-a80e-4a39b20d9587
003SwePub
008230130s2008 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/d8184a98-8c7f-41d6-a80e-4a39b20d95872 URI
0247 a https://doi.org/10.1056/NEJMoa0760162 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Lassen, Michael Ru Nordsjællands Hospital4 aut
2451 0a Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
264 1c 2008
520 a BACKGROUND: We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.METHODS: In this randomized, double-blind trial, 2531 patients who were to undergo total knee arthroplasty received either oral rivaroxaban, 10 mg once daily, beginning 6 to 8 hours after surgery, or subcutaneous enoxaparin, 40 mg once daily, beginning 12 hours before surgery. The primary efficacy outcome was the composite of any deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 13 to 17 days after surgery. Secondary efficacy outcomes included major venous thromboembolism (i.e., proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death related to venous thromboembolism) and symptomatic venous thromboembolism. The primary safety outcome was major bleeding.RESULTS: The primary efficacy outcome occurred in 79 of 824 patients (9.6%) who received rivaroxaban and in 166 of 878 (18.9%) who received enoxaparin (absolute risk reduction, 9.2%; 95% confidence interval [CI], 5.9 to 12.4; P<0.001). Major venous thromboembolism occurred in 9 of 908 patients (1.0%) given rivaroxaban and 24 of 925 (2.6%) given enoxaparin (absolute risk reduction, 1.6%; 95% CI, 0.4 to 2.8; P=0.01). Symptomatic events occurred less frequently with rivaroxaban than with enoxaparin (P=0.005). Major bleeding occurred in 0.6% of patients in the rivaroxaban group and 0.5% of patients in the enoxaparin group. The incidence of drug-related adverse events, mainly gastrointestinal, was 12.0% in the rivaroxaban group and 13.0% in the enoxaparin group.CONCLUSIONS: Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding. (ClinicalTrials.gov number, NCT00361894.)
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng
653 a Adult
653 a Aged
653 a Aged, 80 and over
653 a Anticoagulants/adverse effects
653 a Arthroplasty, Replacement, Knee
653 a Double-Blind Method
653 a Enoxaparin/adverse effects
653 a Factor Xa Inhibitors
653 a Female
653 a Humans
653 a Male
653 a Middle Aged
653 a Morpholines/adverse effects
653 a Pulmonary Embolism/epidemiology
653 a Rivaroxaban
653 a Thiophenes/adverse effects
653 a Venous Thromboembolism/epidemiology
653 a Venous Thrombosis/epidemiology
7001 a Ageno, Walteru University of Insubria4 aut
7001 a Borris, Lars Cu Aarhus University Hospital4 aut
7001 a Lieberman, Jay Ru University of Connecticut4 aut
7001 a Rosencher, Nadiau Cochin Hospital4 aut
7001 a Bandel, Tiemo Ju Bayer Corporation, USA4 aut
7001 a Misselwitz, Franku Bayer Corporation, USA4 aut
7001 a Turpie, Alexander G Gu McMaster University4 aut
7001 a Levine, M4 cre
7001 a Flondell, M.u Lund University,Lunds universitet,Medicinska fakulteten,Faculty of Medicine4 cre0 (Swepub:lu)med-mfd
7001 a Wykman, A4 cre
7102 a Nordsjællands Hospitalb University of Insubria4 org
7102 a RECORD3 Investigators
7730 t The New England journal of medicineg 358:26, s. 86-2776q 358:26<86-2776x 0028-4793
8564 u http://dx.doi.org/10.1056/NEJMoa076016y FULLTEXT
8564 8u https://lup.lub.lu.se/record/d8184a98-8c7f-41d6-a80e-4a39b20d9587
8564 8u https://doi.org/10.1056/NEJMoa076016

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy